Total Quality Requires Total Control

You can build total quality into every stage of your product lifecycle in a way that empowers you to balance control and innovation confidently.

FACE NEW CHALLENGES

Total Quality

Leveraging quality as an asset rather than a constraint enables Life Sciences companies to improve the patient experience and outcome while reducing cost – a win win for all.
 

The goal is to adopt a risk based approach, leveraging data for predictability and creating an integrated framework for compliant innovation, embedding quality and regulatory best practices early in the development process, and providing end-to-end product traceability throughout the lifecycle of the product. This process allows for higher quality, compliant products and faster regulatory approvals.
Ensure full regulatory compliance to:

Medidata RBQM

The Medidata RBQM framework offers the right capabilities that Life Sciences companies need to execute a successful RBQM strategy. This framework provides a simple, easy-to-follow approach that highlights the best entry point for your organization.

ADOPT THE STRATEGY

Regulatory Intelligence to Drive Global Strategy

An integrated framework for compliant innovation, with embedded quality and regulatory best practices will help meet the demands of both government regulators and patients while simultaneously demonstrating value and reducing costs.

Dassault Systèmes' Life Sciences industry solutions and the 3DEXPERIENCE® platform help consign disconnected, manual processes to the past for better efficiency and control, and total quality outcomes in the present. With the Dassault Systèmes 3DEXPERIENCE platform you can:

  • Unify laboratory processes
  • Use simulation to virtualize in 3D
  • Transform quality into business excellence 
  • Ensure a consistent approach to quality, compliance, and regulatory activities 
  • Reduce risk of non-compliance, and improve traceability
  • Enhance decision making
  • Reduce total cost (time, man days) of managing quality 

Tracking Drug Development Cost Savings Through Risk-Based Monitoring

As drug development costs continue to rise, the Life Sciences industry is under increasing pressure to improve efficiency and increase operating speed. In this article, the Drug Information Association (DIA) discusses costing strategies for sustainable drug development in a session at the DIA conference chaired by Tufts Center for the Study of Drug Development's senior project manager Stella Stergiopoulos.

Explore our Industry Solutions Experiences

Discover Dassault Systèmes®' Life Sciences industry solutions aiming to improve patient and physician experience, and organizational business excellence.

More Life Sciences & Healthcare Challenges